Oncological outcomes of BCG unresponsive non-muscle invasive bladder cancer patients treated with chemohyperthermia: A multicentre European retrospective analysis.
BAUS ePoster online library. Tan W. Jun 24, 2019; 259512; P2-8
Dr. Wei Shen Tan
Dr. Wei Shen Tan
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
INTRODUCTION

We report oncological outcomes of patients with BCG unresponsive disease treated with conductive chemohyperthermia (CHT) in a large multicentre European patient cohort.

Methods

CHT was delivered using the Combat BRS system comprised of MMC delivered at 43◦C over 60 minutes. BCG-unresponsive NMIBC was defined as papillary disease ± carcinoma in situ (CIS) <12 months of last BCG instillation, or recurrent high grade papillary disease <6 months of last BCG instillation, or stage T1 disease at first 3 month cystoscopy following induction BCG. Primary endpoint was the 12-month recurrence-free survival (RFS) and the progression-free survival (PFS).

Results
A total of 87 patients from 14 European institutions with a median age of 73.3 years (64.0-79.1) were included. Twenty three patients (26.4%) had CIS only disease, 52 patients (59.8%) with papillary only disease and 12 patients (13.8%) with concurrent CIS and papillary disease. Of the 64 patients with papillary disease, 35 patients (54.7%) had Ta and 29 patients (45.3%) T1 NMIBC. Sixty six patients (75.9%) had high-risk disease. With a median follow-up of 15 (IQR: 8-29) months, 44 patients developed disease recurrence. RFS at 12 months was 55% and at 24 months was 48%. PFS at 24 months was 95%. In patients with CIS disease, 6-month complete response rate was 57%.

Conclusions
BCG-unresponsive NMIBC patients who are treated with CHT delivered using the Combat BRS system had a 24-month DFS of 48% and PFS of 95%. CHT may be an option in NMIBC patients who are unresponsive to BCG.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings